Advanced searches left 3/3
Search only database of 8 mil and more summaries

Vaccine Manufacturers

Summarized by PlexPage
Last Updated: 02 July 2021

* If you want to update the article please login/register

General | Latest Info

The Global Vaccine Market is expected to grow at a CAGR of ~5. 2% from 2019 to 2027 to reach $62. 2 billion by 2027. Vaccines represent one of the greatest achievements of science and medicine in the fight against infectious diseases. Vaccination is one of the most cost - effective public health tools to prevent infectious diseases. Significant progress has been made in expanding coverage of vaccines globally, resulting in the prevention of more than two million deaths annually. The growth of this market is mainly attributed to high prevalence of diseases, increasing government initiatives towards immunization, rising adoption of vaccines, technological advancement in the vaccine industry, and a strong pipeline for vaccines. According to Global Burden of Diseases and Institute For Health Metrics and Evaluation, number of deaths caused by Vaccine - preventable diseases such as tuberculosis decreased from 1. 7 million in 2000 to 1. 2 million in 2016. Moreover, although the incidence of hepatitis is increasing year on year, number of deaths caused by Hepatitis B has decreased from 33. 8 thousand in 2005 to 21. 4 thousand in 2016. Decreasing incidence of death caused by Vaccine - preventable infectious and other diseases is evidence for high adoption of vaccination. Here are the top 10 companies operating Global Vaccines Market - incorporate in 1994 and headquarters in Paris, France, Sanofi is one of the leading players in the Pharmaceuticals Market. The company is engaged in research, development, manufacture, and marketing of therapeutic solutions. Companies operate through three segments, namely, Pharmaceuticals, Consumer Health, and Vaccines via Sanofi Pasteur. Companies sell vaccines in five areas: pediatric vaccines, influenza Vaccines, adult and adolescent booster Vaccines, meningitis Vaccines, and travel and endemic Vaccines. Sanofi Pasteur SA operates in about 150 countries. Annually, more than 500 million people around the world receive company vaccines and units provide more than 1 billion vaccine doses. Found in 1891 and headquarters in New Jersey, US; Merck & Co., Inc. Is global research - driven Pharmaceutical Company engaged in discovery, development, manufacturing and selling of Pharmaceuticals and Vaccines for human and animal healthcare markets. The pharmaceutical segment of the company includes human Health Pharmaceutical and Vaccine products. Companies have a strong footprint across the globe. Outside the US, company has its major operations in Europe, Japan, Asia - Pacific, and Latin America. Founded in 2000 and headquarters in Brentford, UK; GlaxoSmithKline plc is a Pharmaceutical, biological, and Healthcare company engaged in development, manufacture, and marketing of Pharmaceutical and Consumer Health - related products. Gsk operates through three industry segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Through its vaccine segment, company focuses on bringing differentiate, high - quality, and needed vaccines. Currently, company has more than 10 vaccines in the pipeline. The Companies operates in almost 120 countries and its products are sold in over 150 countries worldwide. The company is headquarters in Middlesex, in UK founded in 1849 and headquarters in New York, US, Pfizer Inc. Is one of the leading research - base global biopharmaceutical companies. Pfizers Global portfolio includes medicines and vaccines, and Consumer Healthcare products.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Global Vaccine Industry Outlook

Table

ATTRIBUTEDETAILS
Study Period2016-2027
Base Year2019
Forecast Period2020-2027
Historical Period2016-2018
UnitValue (USD billion)
SegmentationBy Type Recombinant/Conjugate/Subunit Inactivated Live Attenuated Toxoid

The global Vaccine industry is forecast to experience rapid growth spearheaded by leading vaccine manufacturers in the world. Who makes different types of vaccines. The recent global pandemic of COVID - 19 has also had a huge positive impact on this market as many of the world's top vaccine companies are now focussing on developing the most effective vaccination to combat this highly infectious and life - threatening virus, know as Coronavirus. The Global Vaccine Market is expected to register strong growth over the next five years as there is intense competition among a list of vaccine manufacturers that are placing greater emphasis on Research and Development of Live Vaccines. The list of vaccines that are commonly administered includes diseases like chickenpox, diphtheria, Influenza, Meningococcal, and Hepatitis. Several leading vaccine manufacturers are spending heavily on developing vaccinations for babies and vaccination schedules for adults in the wake of the rising number of diseases that can be prevented with vaccines. According to the latest Market Report from Technavio, Global Vaccine Market size has potential to grow by USD 13. 81 billion during 2020 - 2024, registering a strong CAGR of 7% during the Forecast Period. For more information about the Global Vaccine Market size, top vaccine manufacturers, and future trends in this Market, check Technavios Global Vaccines Market Report 2020 - 2024, or request your Global Vaccines Market Report Sample for FREE


Vaccine Market

The recent incidence of coronavirus infection has affected millions of people across the globe. Community transmission in some regions has resulted in increasing casualties worldwide. Currently, biopharmaceutical and biotechnological companies are focusing on increasing research and development of vaccines for COVID - 19. The coronavirus outbreak has offered unprecedented demand and firms are extensively investing in R & D activities along with funding from the government. Expansion of manufacturing facilities catering to huge demand will further strengthen the industry's growth potential. Viral infections are one of the major threats affecting the majority of the population in developing as well as developing nations. Owing to the growing incidence of infectious diseases such as hepatitis virus and human papilloma virus, vaccine market will foresee tremendous growth. However, stringent regulatory policies will affect the development process. Moreover, high storage and transportation costs of vaccines can hamper supply in the market to some extent. Get more details on this report - Request Free Sample PDF

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

Scope of the Report:

Report MetricDetails
Market size available for years20172024
Base year considered2018
Forecast period20192024
Forecast unitsValue (USD)
Segments coveredTechnology, type, disease indication, route of administration, patient type, and region
Geographies coveredNorth America, Europe, Asia, and the Rest of the World
Companies coveredGlaxoSmithKline plc (UK), Pfizer, Inc. (US), Sanofi Pasteur (France), Merck Co., Inc. (US), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson Johnson (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E (India), Bharat Biotech (India), Sinovac Biotech Ltd. (China), Incepta Vaccine Ltd. (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), and PT Bio Farma (Brazil).
* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

How do Vaccines Work?

Influenza Vaccine production and distribution in the US are primarily private sector endeavors. Cdc does not have authority, resources or relationships with providers necessary to carry out or control vaccine distribution. Cdc encourages Influenza Vaccine Manufacturers and distributors to use a distribution strategy that provides Vaccine to all provider types in a comparable timeframe. Such approach allows the broadest possible access to vaccine throughout the season and is consistent with National data that indicate adults in the United States receive Influenza Vaccine in a wide variety of venues, including private provider offices, worksites, clinics, hospitals, health departments, retail settings, and senior centers. While there is a relationship between age or health status and the location in which Vaccines are receive, data demonstrates that all of these venues serve at least some elderly or high risk patients. The timing of completion of Influenza Vaccine production varies from year to year and depends upon a number of factors, including strains chosen for inclusion in the vaccine. Even in year in which each step of production goes well, since Influenza Vaccine Manufacturers are currently producing Vaccine at or near full capacity, it isnt possible for all of doses to be produced and distributed before the beginning of vaccination season. To allow as many providers as possible to begin vaccinating early in the season, CDC encourages manufacturers and distributors to use a distribution strategy in which partial shipments are used to allow as many providers as possible to begin vaccination activities early in the vaccination season. Ideally, intervals between shipments are short so that each provider has continuous supply and can continue vaccinating patients without interruption. Manufacturers say that, because of the unpredictable nature and complexity of biologic production, they cannot always anticipate when vaccine lots will be completed and release. Distributors must rely on manufacturers to provide them with this information. Both manufacturers and distributors are reluctant to project very far into the future about when shipments will be made because they do not want to create unrealistic expectations among customers. The primary reason for variation in timing is because different types of vaccine providers receive their vaccine from different sources. A Provider may order Influenza Vaccine directly from the manufacturer; from the distributor, WHO is customer of manufacturer; or from a secondary distributor, from whom the provider also receives other medical products. Some of these routes of distribution are more direct than others, which can affect timing of vaccine delivery. Influenza Vaccine production begins as early as 6 to 9 months before beginning of vaccine distribution. Even with this early start, it isnt possible to complete the entire production and distribution process prior to flu season, in part because of the limited number of Influenza Vaccine manufacturing plants in the United States and the large number of doses that are produced each year. Instead, Influenza Vaccine distribution takes place in phased fashion over a number of months.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Background: Industry Structure And Shortages

Give fact that there is only a single manufacturer for several childhood vaccines, vaccine stockpiles remain best protection against interruptions in supply or increases in demand for these vaccines in the short to medium term. However, to be fully useful, issue surrounding SEC ruling on Vaccine manufacturers ' realization of income must be resolved and there must be adequate appropriations to complete purchasing Vaccine for stockpiles. Expanding and improving the National Vaccine Injury Compensation Program would mitigate one of the factors that manufacturers take into account when deciding whether to enter the market. Attracting additional manufacturers for existing vaccines is another step that could help minimize the likelihood of shortages. Whether the market is large enough to be enticing is unclear. However, regulatory harmonization would make it easier to import vaccines licensed in other countries and to meet regulatory requirements that are equivalent to those in the United States. Assuring adequate funding to purchase needed supplies of vaccine would avoid shortages based on inadequate resources. In developing world, this is probably the most important step needed As demonstrated by experience with PCV7, financing can also be a constraint in developed countries, although this was not a key factor in recent shortages of PCV7. Gavi is leading efforts to enhance resource availability for developing countries. For Influenza Vaccines in the interpandemic period, probably the most important step to take to avert future shortages would be to establish contracts for guaranteed purchase of Vaccine.S This would markedly reduce financial risk to manufacturers. Establishing adult Immunization Program infrastructure and Vaccine purchase Program under Section 317, combined with an education campaign to increase demand, could help increase the market and stimulate other manufacturers to enter it. For pandemic Influenza Vaccines, most important steps are to develop methods of Vaccine development / production that take less time than current egg - base methods and to establish clearly what the government's role will be in purchase and distribution of pandemic Influenza Vaccine. Even if these steps are take, shortages of pandemic Influenza Vaccine are highly likely in early phases of the pandemic. However, delay between identification of pandemic strain and availability of vaccine could be shortened considerably and the capacity of industry to rapidly scale up vaccine production could be enhance. Some steps could be taken to alleviate total shortages resulting from the absence of vaccine to protect against diseases that are important in the developing world. These include increasing governmental support for research and development, enhancing private - public partnerships, and advance purchase agreements.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Study Methods

Vaccine Manufacturing comprises several stages. In first step, antigen inducing immune response is produce. Since viral antigens are normally present by native Virus, Vaccine manufacturing has historically depended on Virus growth in cultured primary cells, continuous cell lines or chicken eggs for production of whole viral particles. Moreover, growth of bacteria - specific viruses in bacteria grow in bioreactors can be employed for manufacturing of bacteriophages for Phage - Display and, more recently, for development of bacterial vaccines. Nowadays, further development of recombinant protein production technology allows expression of isolated antigenic peptides in organisms such as bacteria, yeasts and mammalian cell lines, increasing the consistency of upstream and downstream processes. In the second step, viral particles are collected and further process. Non - attenuate viruses may need to be inactivated through chemical or physical methods, but generally no further purification is require. Recombinant proteins, on the other hand, require further purification steps including ultrafiltration and column chromatography. In its final step, vaccine is formulated by adding adjuvant, stabilizers, and preservatives as needed. Adjuvants enhance immune response against antigen, stabilizers increase storage life, and preservatives allow use of multidose vials. Vaccine Manufacturing is evolving. Culture mammalian cells are expected to become increasingly important over conventional options that use chicken eggs. Vaccine Manufacturing relies on mammalian cells due to greater productivity and low incidence of problems with contamination versus vaccine Manufacturing using eggs. Recombinant technology that produces genetically detoxified vaccines is expected to grow in popularity for production of bacterial vaccines that use toxoids. Combination Vaccines are expected to reduce the quantities of antigens they contain, and thereby decrease undesirable interactions, by using pathogen - associated molecular patterns. There are many cost pressures when manufacturing vaccines. Producing vaccine in eggs has been historical practice with vaccine manufacturing using cell lines being the more recent endeavor. Having critical cell number, producing most vaccine possible, and reducing variables or tedious downstream activities is a must for Vaccine Manufacturing. While some manufacturers have successfully produced Vaccines for decades, others have faltered or fail, and relatively little information is available in literature on the challenges, complexity and cost of Vaccine manufacturing. Outcomes can vary widely due to nearly infinite combinations of biological variability in basic starting materials, microorganism itself, environmental condition of microbial culture, knowledge and experience of manufacturing technician,sss and steps involved in purification processes. Regulatory authorities License not only specific biological entity, but also the processes by which that entity is produce, test, and released for use. Subtle changes in the production process may alter the final product and change its purity, safety, or efficacy. Many vaccine patents protect the manufacturing process rather than antigen that is produced by the process. Emphasis on process development is a major success factor in being first to market with new biopharmaceuticals and inadequate process development is often implicated in late stage product development failures.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Study Results

Pfizer could have results from its late - stage coronavirus Vaccine trial AS early AS October, CEO Albert Bourla said Thursday. Pharmaceutical companies have already enrol 23 000 volunteers in a Phase three trial that began in late July, Bourla said during Q & with the International Federation of Pharmaceutical Manufacturers & Associations, trade Group. It hop to enroll at least 30 000 participants, he say. We expect by the end of October, we should have enough. To say whether the product works or not, he say. US Health officials have previously said results from late - stage Vaccine Trials could come in November or sooner. Pfizer's potential vaccine is one of three back by the US that's currently in late - stage testing. Us - base Pharmaceutical giant has been working alongside German drugmaker BioNTech. Companies experimental vaccines that contain genetic material called messenger RNA, or mRNA. In July, company released promising data from its early - stage trial. The Phase three trial is expected to include up to 30 000 participants between the ages of 18 and 85 across 120 sites globally, including 39 US States, company has say. If it is successful, they expect to submit it for final regulatory review AS early AS October. They plan to supply up to 100 million doses by the end of 2020 and approximately 1. 3 billion doses by the end of 2021. In July, US government announced it would pay Pfizer and BioNTech $1. 95 billion to produce and deliver 100 million doses of their vaccine if it proves safe and effective. The deal was signed as part of Operation Warp Speed, Trump Administration's effort to accelerate development and production of vaccines and treatments to fight coronavirus. The CEO's remark came AS Centers for Disease Control and Prevention is asking state governors and local Health departments to prepare to distribute Vaccine AS SOON AS November. The deadline is raising concerns among Public Health experts and scientists that approval of the vaccine will be politically motivated and the White House may be pressuring regulators to get the vaccine to market ahead of the presidential election on Nov. 3. Drug company executives, including from Pfizer, have previously insisted they aren't cutting corners in fast - tracking development of potential vaccines. They have said the Food and Drug Administration hasn't eased its requirements for proving their vaccines are safe and effective. While the vaccine may be safe, executives have said it is understandable the public would be concern, adding they will need to work to gain that trust. Vaccine hesitancy is probably one of the greatest challenges to public health that America face, John Young, Pfizer's chief business officer, told Congress on July 21. All of US needs to play a role, should we be successful in this mission, that there's confidence in the safety and effectiveness of our vaccines based on data, Based on confidence, FDA will only approve vaccine if it's safe and effective. Bourla said Thursday that the company would never submit any Vaccine for Authorization before we feel it is safe and effective.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Discussion

Numerous COVID - 19 Vaccine players are racing ahead at record speeds, and while a group of front - runners has taken shape, other companies in earlier stages of research are already busy with launch preparations. More than 160 groups are working on COVID - 19 Vaccines, and 24 candidates have already reach human testing, according to the World Health Organization. Some are gearing up for Phase 3, and officials and execs alike have said vaccines might be ready later this year or early next. When they are, vaccine makers will have to answer one big question: At what price? Johnson & Johnson and AstraZeneca have pledged to Market Vaccines no profit during the pandemic, while the Pfizer CEO has said the company plans to price for marginal profit. Novavax plans to make an appropriate return. Moderna's CEO has pledged to price in line with other respiratory Virus Vaccines. At other companies, discussions are ongoing. Execs for many of companies involved in the vaccine race are set to testify at Tuesday's hearing in Congress, where pricing is expected to be one topic of discussion.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

NOTES

Cdc's National Center For Immunization and Respiratory Diseases develops and maintains HL7 Table 0227, Manufacturers of Vaccines. The table below is the most up - to date value set for this table. It includes both active and inactive Manufacturers of Vaccines in the US. Inactive MVX codes allow transmission of historical immunization records. When MVX code is paired with CVX code, specific trade name Vaccine may be indicate. The Status Column indicates if manufacturer is currently making vaccine for distribution in the United States. The Last Updated Column indicates the last time this particular manufacturer code was Update in this Table. Questions regarding this table should be directed to IIS Technical Assistance Team. Sort Table by Column: Simply click on the column heading to sort table accordingly. For further information on HL7 Immunization data Exchange and CVX code set, contact IIS Technical Assistance Team at:

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

VACCINE PRODUCTION

The landscape in Vaccine Manufacturing has changed radically over the past 30 years. In 1967, over a dozen licensed vaccine manufacturers operated in the United States alone. This number has since collapsed through mergers and exits to barely a handful 1. Low profit margins, introduction in 1980 of Good Manufacturing Practices to Vaccine production and the specter of liability all contributed to contraction in industry. Five companiesChiron, GlaxoSmithKline, Merck, Sanofi Pasteur and Wyeth, account for close to 90% of Influenza Vaccine supply in the world. Now the landscape may be about to change again, as attention is rivet on vaccine supplies, in anticipation of a possible Influenza Pandemic. The price for Vaccine has jumped from a few dollars for the course of routine pediatric vaccines in the 1980s to over $200 for Wyeth's blockbuster Vaccine Prevnar against meningitis and bloodstream infections. Some say Prevnar has transformed the vaccine business almost overnight. Although vaccine sales on the whole have risen rather modestly over the past 20 years, from $2 billion in 1982 to only over $8 billion todaya, pittance compared with the drug market. As wholerecent, projections show the vaccine market growing at double digits annually, which outpaces other infectious disease sectors 2. The new crop of vaccines, like Merck's Gardasil subtypes 6 11 16 and 18, which were recently shown to be 100% effective in preventing cervical cancer, is projected to bring in $750 million to over $1 billion annually. Keeping up with demand for new vaccines, let alone responding to possible epidemics, natural or man - make, could well overwhelm already stretch - to - capacity manufacturers of these prophylactics. Although vaccine manufacturers are loath to discuss capacity right now in a highly politicized environment created by fear of the Influenza Pandemic, look at their activity suggests that they are concerned about capacity and committed to increasing it. Each of the top five vaccine - producing companies has increased capacity either through acquisitions or through building facilities from scratch table 1. The flurry of big pharma merger and acquisition activity this fall, which focused on targets with large Influenza Vaccine franchises, underlines the extent to which vaccines are now considered worthwhile investment opportunity by industry's biggest guns. Glaxosmithkline's $1. 4 billion bid for ID Biomedical, of Vancouver, Canada, and Basel - base Novartis's attempt to become outright owner of Chiron are evidence of ongoing revival of this previously viewed low - profit, Cinderella sector. Several factors have kept new companies from entering the fray, and might continue to do so going forward, even with optimistic market projections. The high level of capital expenditure involved in vaccine production, combined with its complexity table 2, have enabled larger players to maintain their dominance. Many vaccines are low - margin products, so large economies of scale, combined with deep production experience, have proven effective barriers to entry. Every single step in manufacture of vaccine is extremely challenging, says Philippe Monteyne, vice president of worldwide cervical cancer Vaccine Cervarix operations with GSK Biologicals.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

COST STRUCTURE 1

Costs of vaccine production include research and development costs; costs relating to regulatory approval process; ongoing regulatory costs; plant costs, including depreciation; marketing costs; variable costs for labor, production, equipment, and supplies; and liability costs. Although there are substantial differences between development costs for vaccines and pharmaceuticals, latter provides a useful benchmark. It has been estimated that, between 1980 and 1984, R & D and regulatory approval processes generated an average of 11 years of negative cash flow for NCEs introduced in the US Pharmaceutical industry. Dimasi et al. Estimate mean out - of - pocket cost for successful NCE at $32 million in 1987 dollars; when discovery, clinical testing, and failure costs are include, this figure rises to $115 million, while inclusion of time and interest costs results in an estimate of $231 million. A more recent study by DiMasi indicates that the out - of - pocket cost of NCE has escalated to $403 - $802 million when the time lag between investment and market release is capitalize. Total development costs of bringing Vaccine to market are roughly similar to those for drugs and can be higher. As part of the initial approval process, FDA requires that Vaccines used in Phase III clinical trials be produced in a facility that will be used for commercial production if the Vaccine is approve. As a result, manufacturers must frequently invest more than $30 million in production facility prior to product approval. Vaccine development costs have also risen as a result of the increased time it takes to achieve license as well as larger FDA - required Phase III clinical trials for many recent Vaccines. The size of clinical trials depends on the number of variables, including rates of disease and anticipated adverse events. The average size of clinical trials has increased over time to provide an adequate basis for identifying rare adverse effects during Vaccine development. One industry expert estimates that new vaccine cost $700 million from initial research to commercial production. In addition to the requirement for early facility investments, production facilities for vaccines tend to be more capital - intensive than those for pharmaceuticals. On the other hand, vaccines tend to have higher success rates than pharmaceuticals and may be characterized by faster development times. Once the vaccine has been approve, production process involves high fix costs relative to variable costs. Fix production costs, exclusive of up - front R & D and sales labor, represent 60 percent of total production costs for Vaccines. These fixed costs are not affected by changes in production volume. They are associated primarily with quality assurance activities, administrative labor, depreciation, and other manufacturing overhead. Industry representatives have indicated that increased regulatory requirements have resulted in increased costs for quality assurance employees relative to production employees. Semivariable costs make up 25 percent of total costs, excluding R & D and sales labor. Semivariable costs are batch costs that are constant per batch regardless of number of batches.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

RESEARCH AND DEVELOPMENT

Vaccines are one of the greatest public health advancements of all time, resulting in control, elimination, or near - elimination of numerous infectious diseases that were once pervasive and often fatal. Pfizer has a rich history of Vaccine Research and Development. Over the years, weve played a pivotal role in eliminating or nearly eliminating deadly infectious diseases like smallpox and polio globally. We have designed novel Vaccines based on new delivery systems and technologies that have resulted in Vaccines to prevent bacterial infections, like those caused by S. Pneumoniae and N. Meningitidis. Nanette Cocero is Global President of Pfizer Vaccines. In her role, Nanette oversees International Business and is responsible for development and delivery of Innovative Vaccines that address serious and life - threatening conditions, helping to protect communities around the world. Nanette leads a global team of 1 500 colleagues and manages a diverse vaccine portfolio aimed at protecting lives at all stages, from infants to older adults. She and her team also partner with governments, civic organizations, and others in the biopharmaceutical industry to accelerate global public health progress. She is Chair of the International Federation of Pharmaceuticals and Manufacturers Association Vaccine CEO Steering Committee, advocating for policies and practices that will enable greater access and affordability to vaccines in low and middle - income countries. In addition, Nanette is a Board member of the Americas Society / Council of Americas. Prior to her current position, Nanette was Regional President, Emerging Markets, for Pfizers Innovative Health Business. In this role, she leads business operations in over 100 countries across Latin America, Africa, Middle East, and Asia, spanning Pfizer's core therapeutic areas including Vaccines, oncology, inflammation and immunology, internal Medicine and rare Disease. During her 15 + year tenure at Pfizer, Nanette has held numerous leadership positions in both developed and emerging markets, driving continuous growth for businesses she manages and bringing novel medicines and access solutions to patients. Before joining Pfizer, Nanette worked for 10 years as an AS Management consultant and served as an AS Research Fellow for the University of Pennsylvania, Department of Pharmacology. Nanette earned a Bachelor of Science degree in chemistry from Cornell University; ph. D in Pharmacology from the University of Pennsylvania, and MBA from Wharton Business School. She has lived and worked in the continental United States, Puerto Rico, and Spain and she is bilingual in English and Spanish. Kathrin U. Jansen, PhD, is Senior Vice President and Head of Vaccine Research and Development at Pfizer Inc, and member of the Pfizer Worldwide Research and Development leadership team. Dr. Jansen oversees fully integrate, Global Vaccines Research and Development Organization, with responsibilities ranging from discovery to registration and post - Marketing commitments of first - in - class or best - in - class Vaccines to prevent or treat diseases of significant unmet medical need. More recent accomplishments are Global licensures of prevnar13 to prevent pneumococcal Diseases and Development and licensure of Trumenba, first Vaccine license in the United States to prevent invasive Disease caused by Neisseria meningitidis serogroup B. Dr.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Sources

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

logo

Plex.page is an Online Knowledge, where all the summaries are written by a machine. We aim to collect all the knowledge the World Wide Web has to offer.

Partners:
Nvidia inception logo

© All rights reserved
2021 made by Algoritmi Vision Inc.

If you believe that any of the summaries on our website lead to misinformation, don't hesitate to contact us. We will immediately review it and remove the summaries if necessary.

If your domain is listed as one of the sources on any summary, you can consider participating in the "Online Knowledge" program, if you want to proceed, please follow these instructions to apply.
However, if you still want us to remove all links leading to your domain from Plex.page and never use your website as a source, please follow these instructions.